Dutasteride can reduce intraoperative bleeding during transurethral resection of the prostate: Evaluation of vascular endothelial growth factor (VEGF) and CD34

Trial Profile

Dutasteride can reduce intraoperative bleeding during transurethral resection of the prostate: Evaluation of vascular endothelial growth factor (VEGF) and CD34

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2014

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 May 2014 New trial record
    • 11 Apr 2014 Results presented at the 29th Congress of the European Association of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top